With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...

GSK announces new strategic investments in Africa to increase access to medicines, build capacity and deliver sustainable growth - Creates world's first R&D Open Lab to increase ...

GSK will fund R&D activities at CureVac related to the development projects covered by the collaboration. GSK will make an equity investment in CureVac of 130 million pounds, ...

She added that GSK may be getting more bang per buck in terms of its R&D investment, with seven drugs in pre-registration phase compared with Celgene’s eight at the same stage of development.

The company has also worked to make R&D more efficient by laying off more than 25% of the R&D staff since 2006. The company also reduced lab space by more than 15%.

GlaxoSmithKline (GKS, London) outlined a plan to invest EUR 500 million ($649 million) in research and development (R&D) and related manufacturing in the United Kingdom conditioned on the successful ...

Could GlaxoSmithKline Be A Better Investment Than Gilead? Sep. 17, 2014 10:06 AM ET GSK plc (GSK) Stock GILD, GSK 22 Comments. William Meyers. 7.5K Followers. ... across the R&D pipeline, ...

GlaxoSmithKline announced Monday it plans to invest $139 million in expanding production of its lupus drug, Benlysta, in its Rockville location on Belward Campus Drive.

By Maggie Fick and Natalie Grover. LONDON, April 26 (Reuters) - British drugmaker GSK on Wednesday warned that the overhaul of laws governing the EU's pharmaceuticals industry risks forcing ...